20/20 Biolabs, Inc. Income Statement
AIDX|1 years of annual SEC 10-K data (FY2025-FY2025)
Line items include revenue, cost of goods sold, gross profit, operating expenses, interest, taxes, and net income with per-share data. All figures from audited SEC 10-K filings.
20/20 Biolabs, Inc. reported $2M in revenue and $4M in net loss for FY2025. Its profit margin was -182.8% in FY2025.
Based on SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -8.99 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 |
|---|---|
| Revenue | $2.0M |
| Cost of Revenue | $1.4M |
| Gross Profit | $604.5K |
| SG&A Expense | $3.3M |
| R&D Expense | $592.6K |
| Operating Income | -$3.3M |
| Net Income | -$3.7M |
| EPS (Basic) | -$1.16 |
| EPS (Diluted) | -$1.16 |
| Shares Outstanding | 4.8M |
| Gross Margin | 29.6% |
| Operating Margin | -162.9% |
| Profit Margin | -182.8% |